



File Number 90/15764

PERMIT TO IMPORT

THERAPEUTIC SUBSTANCE(S) UNDER REGULATION 5A
OF THE CUSTOMS (PROHIBITED IMPORTS) REGULATIONS

Number
19386

LT

This permit is to be presented to the Collector of Customs at the port of entry

Importer's
Name and
Address

Officer Commanding
Randwick Supply Company
Avoca Street, RANDWICK NSW 2031

Permission is granted to the above named to import into Australia the following therapeutic substance(s) under the above stated Regulations (where applicable, the application to import has been subjected to quarantine scrutiny):

Three thousand three hundred (3,300) Atropine Sulphate
Auto-Injector each containing 2mg of atropine sulphate
manufactured & supplied by Duphar BV, Amsterdam, The
Netherlands

THIS PERMISSION IS SUBJECT TO THE FOLLOWING REQUIREMENTS OR PROHIBITIONS:

1. This permit is a LIMITED AUTHORITY for the importation of the above stated quantity (ies) ONLY.
2. The importer is required to keep records with respect to the custody, use, disposal or distribution of the above therapeutic substance(s) for a period of three years from the date of importation.

3. For use in combat zone only. Not for general distribution in Australia.
As this Dept has not evaluated any data for this product, no
guarantee of quality, safety or efficacy are given or implied

THIS PERMISSION IS ALSO SUBJECT TO THE PROHIBITIONS OR REQUIREMENTS SPECIFIED WITH AN 'X' BELOW:

- ☐ for invitro (diagnostic) use ONLY.
- ☐ to be labelled 'CAUTION MAY BE INFECTIOUS'.
- ☐ Australian Radiation Laboratory approval to import also required.
- ☐ for personal use ONLY - NOT to be distributed for use by other persons or in animals.

- ☐ for delivery into store ONLY - distribution may NOT take place without permission of the Secretary.
- ☐ for supply to approved users ONLY.
- ☐ for laboratory animal use ONLY.
- ☐ for veterinary use ONLY.
- ☐ NOT to be used in animals.

Signature of Authorised Officer for the Secretary

Date

Further applications to import this/these or any other Therapeutic substance(s) should be made in writing to:
The Drug Evaluation Branch, Therapeutic Goods Administration, P.O. Box 100, WODEN ACT 2606, AUSTRALIA